Cybrexa Therapeutics picks up $25m Series B
Cybrexa Therapeutics, an oncology-focused biotechnology company, has closed $25 million in Series B financing.
Cybrexa Therapeutics, an oncology-focused biotechnology company, has closed $25 million in Series B financing.
Copyright PEI Media
Not for publication, email or dissemination